Rituximab-associated changes in platelet count in patients with non-Hodgkin lymphoma.
Rituximab is a monoclonal antibody specific for the CD20 antigen. Clinical factors associated with thrombocytopenia after administration of rituximab have only been reported as case reports. We have analysed retrospectively the change of platelet counts following the administration of rituximab in 253 patients with non-Hodgkin lymphoma (NHL). Correlations with clinical and laboratory parameters were assessed. A mean overall decrease in platelets was observed after rituximab infusion. A downward trend in platelet count of more than 30% was observed in 7.2% of the patients. The decline was observed when rituximab was given as a single agent or in combination with chemotherapy. The risk factors to develop a decline in platelets after infusion of rituximab were pre-existent thrombocytopenia, advanced lymphoma stage, bone marrow infiltration, splenomegaly, leukemic presentation, and Burkitt lymphoma histology. In conclusion, a decline in platelet count after administration of rituximab was observed in patients with NHL, mainly those with pre-existing thrombocytopenia.
Wilop
Stefan
S
Medizinische Klinik IV, Universitaetsklinikum Aachen, Aachen, Germany.
Galm
Oliver
O
Dada
Reyad
R
Osieka
Rainhardt
R
Jost
Edgar
E
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001792:Blood Platelets / Q000187:drug effects*; D001855:Bone Marrow Diseases; D002051:Burkitt Lymphoma; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007938:Leukemia; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D012189:Retrospective Studies; D012307:Risk Factors; D000069283:Rituximab; D013163:Splenomegaly; D013921:Thrombocytopenia; D055815:Young Adult
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab